

REMARKS/ARGUMENTS

I. Status of Claims

Claims 1-32 were originally filed. Claims 1-32 were subject to a Restriction Requirement. After response to the Restriction Requirement, claims 1-32 are elected for prosecution. Claims 1 and 2 are amended to correct typographical and punctuation mistakes. Claims 1 and 2 are also amended to recite proper Markush groups. Claim 28 is amended to correct punctuation mistakes. Claim 28 is also amended to recite a proper Markush group. Claims 29-32 are amended to make the claims clear and concise. New claims 33-42 are added. New claims 33-42 are directed to particular species of Formulae III and IV. No new matter has been added. Support for the new claims may be found throughout the specification.


II. Response to the Restriction Requirement

The claims are restricted into three groups. Applicants elect Group I for prosecution on the merits. The claims of Group I are drawn to a process of modulating an Edg-3 receptor mediated biological activity with carboxamide compounds when X is O. Claims 1-32 fall within Group I. New claims 33-42 also fall within Group I.

The election of the claims of Group I is made with traverse. The claims emerge from a common inventive concept; a process of modulating an Edg-3 receptor mediated biological activity with carboxamide compounds, a process of modulating an Edg-3 receptor mediated biological activity with thiocarboxamide compounds and a process of modulating an Edg-3 receptor mediated biological activity with amidine compounds. The Applicants respectfully submit that searching the process of modulating an Edg-3 receptor mediated biological activity with carboxamide compounds, the process of modulating an Edg-3 receptor mediated biological activity with thiocarboxamide compounds and the process of modulating an Edg-3 receptor mediated biological activity with amidine compounds would not be an undue burden on the Examiner.

III. Response to the Election of Species Requirement

The Examiner has required the Applicants to elect a single species and a disease condition in which the identity of each claim element is explicitly set forth. Applicants elect compound 101 which is set forth below:



Applicants also elect cardiovascular disease as the disease condition. Cardiovascular disease includes but is not limited to ischemia and atherosclerosis.

Applicants submit that pending claims 1, 3-32 and new claims 33-42 are readable on the elected species.

Applicants respectfully submit that such elections are without prejudice and expressly reserve the right to prosecute the non-elected species and claims at a later stage.

CONCLUSION


In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

Appl. No. 10/760,003
Amdt. dated June 23, 2006
Restriction Requirement dated April 25, 2006

PATENT

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-442-1000.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Alok" followed by a stylized monogram or initials.

Alok Goel (Reg. No. 51,745) on behalf of
Thomas D. Kohler (Reg. No. 32,797)

Morgan, Lewis & Bockius LLP
2 Palo Alto Square
3000 El Camino Real, Suite 700
Palo Alto, California 94306
Tel: (415) 442-1000
Fax: (415) 442-1001
1-SF/7373670.1